The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia

Journal of Supportive Oncology

Volumn 6, Issue 6, 2008, Pages 283-290

  Robinson Jr , Donald W ^a,b,c,d   Eisenberg, Debra F ^a,b,c,d   Cella, David ^a,b,c,d   Zhao, Ning ^a,b,c,d   de Boer, Carla ^a,b,c,d   DeWitte, Mark ^a,b,c,d  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c CENTOCOR INC   (United States)

^d Centocor   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; HEMOGLOBIN; INFLIXIMAB; OPIATE; PLACEBO;

ADULT; AGED; ARTICLE; BRIEF PAIN INVENTORY; CACHEXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NUTRITIONAL HEALTH; OVERALL SURVIVAL; PAIN ASSESSMENT; PANCREAS CANCER; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SHORT FORM 36; SURVIVAL RATE; TREATMENT PLANNING; WEIGHT REDUCTION;

ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; APPETITE; CACHEXIA; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PANCREATIC NEOPLASMS; PROGNOSIS; QUESTIONNAIRES; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT LOSS;

EID: 48449095974     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002;2:862-871.[12415256]
2. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006;83:735-743.[16600922]
3. Fearon KC, Moses AG. Cancer cachexia. Int J Cardiol 2002;85:73-81.[12163211]
4. Mantovani G. Cytokines in cachexia. In: Mantovani G, Anker SD, Inui A, et al, eds. Cachexia and Wasting: A Modern Approach. Berlin: Springer Verlag;2006:205-207.
5. Kayacan O, Karnak D, Beder S, et al. Impact of TNF-alpha and IL-6 levels on development of cachexia in newly diagnosed NSCLC patients.Am J Clin Oncol 2006;29:328-335.[16891858]
6. Krzystek-Korpacka M,Matusiewicz M,Diakowska D, et al. Impact of weight loss on circulating IL-1, IL-6, IL-8, TNF-alpha, VEGF-A, VEGF-C and midkine in gastroesophageal cancer patients. Clin Biochem 2007;40:1353-1360.[17931612]
7. Chang VT, Xia Q, Kasimis B. The Functional Assessment of Anorexia/ Cachexia Therapy (FAACT) Appetite Scale in veteran cancer patients. J Support Oncol 2005;3:377-382.[16218262]
8. Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006;24:3394-3400.[16849753]
9. Fearon KC, Voss AC, Hustead DS. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Cancer Cachexia Study Group. Am J Clin Nutr 2006;83:1345-1350.[16762946]
10. Kim HL, Belldegrun AS, Freitas DG, et al. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol 2003;170:1742-1746.[14532767]
11. Hutton JL, Martin L, Field CJ, et al. Dietary patterns in patients with advanced cancer: implications for anorexia-cachexia therapy. Am J Clin Nutr 2006;84:1163-1170.[17093170]
12. Hutton JL, Baracos VE, Wismer WV. Chemosensory dysfunction is a primary factor in the evolution of declining nutritional status and quality of life in patients with advanced cancer.J Pain Symptom Manage 2007;33:156-165.[17280921]
13. Davidson W, Ash S, Capra S, Bauer J. Weight stabilization is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Cancer Cachexia Study Group. Clin Nutr 2004;23:239-247.[15030964]
14. Andreyev HJN, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 1998;34:503-509.[9713300]
15. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980;69:491-497.[7424938]
16. Ross PJ, Ashley S, Norton A, et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancer? Br J Cancer 2004;90:1905-1911.[15138470]
17. Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM.Thalidomide in the treatment of cancer cachexia: a randomized placebo controlled trial. Gut 2005;54:540-545.[15753541]
18. Dewey A, Baughan C, Dean T, Higgins B, Johnson I. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev 2007;1: CD004597.[17253515]
19. Fearon KC, Barber MD, Moses AG, et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 2006;24:3401-3407. [16849754]
20. Berenstein EG, Ortiz Z. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2005;2:CD004310.
21. Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting:a North Central Cancer Treatment Group and National Cancer Institute ofCanada collaborative effort. North Central Cancer Treatment Group. J Clin Oncol 2004;22:2469-2476.[15197210]
22. May PE, Barber A, D'Olimpio JT, Hourihane A, Abumrad NN. Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am J Surg 2002;183:471-479.[11975938]
23. Yavuzsen T, Davis MP, Walsh D, LeGrand S, Lagman R. Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol 2005;23:8500-8511.[16293879]
24. Lundholm K, Daneryd P, Bosaeus I, Körner U, Lindholm E. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: Effects on survival, metabolism, and function. Cancer 2004;100:1967-1977.[15112279]
25. Jatoi A, Dakhil SR, Nguyen PL, et al.A placebo-controlled double-blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from NOOC1 from the North Central Cancer Treatment Group. Cancer 2007;110:1396-1403.[1767435]
26. Bossola M, Muscaritoli M, Bellantone R, et al. Serum tumour necrosis factor-alpha levels in cancer patients are discontinuous and correlate with weight loss. Eur J Clin Invest 2000;30:1107-1112. [11122326]
27. Falconer JS, Fearon KC, Ross JA, et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 1995;75:2077-2082. [7535184]
28. Monk JP, Phillips G, Waite R, et al. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol 2006;24:1852-1859.[16622259]
29. de Witte M, Anderson M, Robinson D. Anti-TNF-α antibody and cancer cachexia. In: Mantovani G, Anker SD, Inui A, et al, eds.Cachexia and Wasting:A Modern Approach. Berlin: Springer Verlag; 2006:673-683.
30. Wiedenmann B, Malfertheiner P, Friess H, et al. Results of a multicenter, phase II study of the safety and efficacy of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol 2008;6:18-25. [18257397]
31. Fayers PM, Hopwood P, Harvey A, Girling DJ, Machin D, Stephens R. Quality of life assessment in clinical trials - guidelines and a checklist for protocol writers:the U.K. Medical Research Council experience. Eur J Cancer 1997;33:20-28.[9071894]
32. Hahn EA, Webster KA, Cella D, Fairclough DL. Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: problems and solutions. Stat Med 1998;17:547-559. [9549804]
33. Hopwood P, Harvey A, Davies J, et al. Survey of the administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. The Medical Research Council Lung Cancer Working Party the CHART Steering Committee. Eur J Cancer 1998;34:49-57.[9624237]
34. Ribaudo JM, Cella D, Hahn EA, et al. Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Quality Life Res 2001;9:1137-1146.[11401046]
35. Jensen MP. The validity and reliability of pain measures in adults with cancer. J Pain 2003;4:2-21. [14622723]
36. Ware JE Jr, Kosinski M. SF-360® Physical & Mental Health Summary Scales:A Manual for Users of Version 1. 2nd ed. Lincoln, RI: QualityMetric Inc; 2001.
37. Mallinson T, Cella D, Cashy J, Holzner B. Giving meaning to measure: linking self-reported fatigue and function to performance of everyday activities. J Pain Symptom Manage 2006;31:229-241.[16563317]
38. Kotler DP, Burastero, S, Wang J, Pierson RN Jr. Prediction of body cell mass,fat-free mass, and total body water with bioelectrical impedance analysis: effects of race, sex, and disease. Am J Clin Nutr 1996;64:489S-497S.[8780369]
39. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-117.[12091180]
40. Bender R, Lange S.Adjusting for multiple testing-when and how? J Clin Epidemiol 2001;54:343-349.[11297884]
41. Schulz KF, Grimes DA. Multiplicity in randomized trials 1: endpoints and treatments. Lancet 2005;365:1591-1595.[15866314]
42. Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002;94:528-538.[11900238]
43. Lee JQ, Simmonds MJ, Wang XS, Novy DM. Differences in physical performance between men and women with and without lymphoma. Arch Phys Med Rehabil 2003;84:1747-1752.[14669178]
44. Simmonds MJ. Physical function in patients with cancer: psychometric characteristics and clinical usefulness of a physical performance test battery. J Pain Symptom Manage 2002;24:404-414. [12505209]
45. Brown DJ, McMillan DC, Milroy R.The correlation between fatigue, physical function,the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer 2005;103:377-382.[15558809]
46. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer:a systematic,quantitative review.Cancer 2001;91:2214-2221.[11413508]
47. Efficace F, Biganzoli L, Piccart M, et al. Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. EORTC-BCG-IDBBC-NDDG. Eur J Cancer 2004;40:1021-1030.[15093577]
48. Glare P. Clinical predictors of survival in advanced cancer. J Support Oncol 2005;3:331-339. [16218255]
49. Hwang SS, Scott CB, Chang VT, Cogwell J, Srinivas S, Sasimis B. Prediction of survival for advanced cancer patients by recursive partitioning analysis: role of Karnofsky performance status, quality of life and symptom distress. Cancer Invest 2004;22:678-687.[15581048]
50. Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002;20:3972-3982.[12351594]
51. Spiro SG, Silvestri GA. The treatment of advanced non-small cell lung cancer. Curr Opin Pulm Med 2005;11:287-291.[15928493]
52. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24:547-561.[12551804]
53. Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship between hemoglobin, fatigue and quality of life in anemic cancer patients; results from five randomized clinical trials. Ann Oncol 2004;15:979-986.[15151958]
54. Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS, Milroy R.The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2002;87:264-267.[12177792]
55. Hwang SS, Chang VT, Cogswell J, Kasimis BS. Clinical relevance of fatigue levels in cancer patients at a Veterans Administration medical center. Cancer 2002;94:2481-2489.[12015774]
56. Vigano A, Donaldson N, Higginson U, Bruera E, Mahmud S, Suarez-Almazor M. Quality of life and survival prediction in terminal cancer patients: a multicenter study. Cancer 2004;101: 1090-1098. [15329920]
57. Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W. Progress toward guidelines for the management of fatigue. Oncology 1998;12:369-377. [10028520]